United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Employees

1,168

Sector

Biotechnology & Medical Research

Calendar

2025-02-18 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-11-29	370.49 $	-2.02%	211,330
24-11-27	378.13 $	+0.30%	323,211
24-11-26	377.00 $	+2.26%	265,053
24-11-25	368.66 $	-1.13%	515,147
24-11-22	372.89 $	+1.51%	257,235

Delayed Quote Nasdaq, November 29, 2024 at 01:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart UNITED-THERAPEUTICS-CORPO

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

370.49USD

Average target price

382.22USD

Spread / Average Target

+3.17%

Consensus

Profit revisions

estimates-change-chart UNITED-THERAPEUTICS-CORPO

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart UNITED-THERAPEUTICS-CORPO

Company calendar

Market Closed - Nasdaq Other stock markets 01:00:00 2024-11-29 pm EST			5-day change	1st Jan Change
370.49 ^USD	-2.02%		-0.64%	+68.49%

Nov. 22	United Therapeutics Insider Sold Shares Worth $2,828,672, According to a Recent SEC Filing	MT
Nov. 12	United Therapeutics Corporation Presents at UBS Global Healthcare Conference 2024, Nov-12-2024 02:45 PM

Capitalization	16.54B 15.68B 14.59B 13.02B 23.17B 1,399B 25.4B 181B 67.24B 574B 62.14B 60.76B 2,489B	P/E ratio 2024 *	15.1x	P/E ratio 2025 *	13.3x
Enterprise value	14.38B 13.63B 12.68B 11.32B 20.14B 1,216B 22.07B 157B 58.44B 499B 54.01B 52.81B 2,164B	EV / Sales 2024 *	4.99x	EV / Sales 2025 *	4.16x
Free-Float	58.58%	Yield 2024 *	-	Yield 2025 *	-

United Therapeutics Insider Sold Shares Worth $2,828,672, According to a Recent SEC Filing	Nov. 22	MT
United Therapeutics Corporation Presents at UBS Global Healthcare Conference 2024, Nov-12-2024 02:45 PM	Nov. 12
BETA Technologies, Inc. announced that it has received $318.437454 million in funding from Qatar Investment Authority, Fidelity Management & Research Company LLC, TPG Capital, L.P., United Therapeutics Corporation and other investors	Oct. 30	CI
United Therapeutics Seeks M&A	Oct. 30	CI
United Therapeutics Corporation, Q3 2024 Earnings Call, Oct 30, 2024	Oct. 30
United Therapeutics' Q3 Earnings, Revenue Rise	Oct. 30	MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Posts Q3 Revenue $748.9M	Oct. 30	MT
Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on March 25, 2024.	Oct. 30	CI
United Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Oct. 30	CI
BETA Technologies, Inc. announced a financing transaction	Oct. 23	CI
United Therapeutics Insider Sold Shares Worth $2,855,916, According to a Recent SEC Filing	Oct. 22	MT
Sector Update: Health Care Stocks Retreat Late Afternoon	Oct. 07	MT
Sector Update: Health Care Stocks Softer Monday Afternoon	Oct. 07	MT

Oppenheimer Raises United Therapeutics Price Target to $575 From $400, Maintains Outperform Rating	Aug. 28	MT
UBS Adjusts Price Target on United Therapeutics to $365 From $370, Maintains Buy Rating	Aug. 01	MT
Ladenburg Thalmann Downgrades United Therapeutics to Neutral From Buy, $319 Price Target	Aug. 01	MT
HC Wainwright Adjusts Price Target on United Therapeutics to $400 From $300, Maintains Buy Rating	Jul. 25	MT
United Therapeutics Insider Sold Shares Worth $2,355,544, According to a Recent SEC Filing	Jul. 17	MT

United Therapeutics Corporation Stock

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Valuation: United Therapeutics Corporation

Chart: United Therapeutics Corporation

Latest news: United Therapeutics Corporation

Last Transcript: United Therapeutics Corporation

Analysts' recommendations: United Therapeutics Corporation

Press Releases: United Therapeutics Corporation

News in other languages: United Therapeutics Corporation

Quotes and Performance

Course Extremes

Managers and Directors: United Therapeutics Corporation

ETFs: United Therapeutics Corporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

United Therapeutics Corporation to Present at the UBS Global Healthcare Conference	Nov. 05	BU
United Therapeutics : Third Quarter 2024 Factsheet	Oct. 30	PU
United Therapeutics : Reports Third Quarter 2024 Financial Results Form 8 K	Oct. 30	PU
United Therapeutics : Third Quarter 2024 Financial Results Presentation	Oct. 30	PU
United Therapeutics: Q3 Earnings Snapshot	Oct. 30	AQ

Pfizer acquiert le laboratoire Arena Pharmaceuticals	21-12-13
MÄRKTE USA/Börse hakt schwache Daten ab - Technologiewerte gesucht	21-10-18
MÄRKTE USA/Erholt von Anfangsverlusten - Technologiewerte vorne	21-10-18
Novartis/Sandoz obtient une extension d'indication pour Treprostinil aux USA	21-05-24
Novartis-Tochter Sandoz erhält Indikationserweiterung für PAH-Medikament in USA	21-05-24

1 day	-2.02%
1 week	-0.64%
1 month	-0.93%
3 months	+1.91%
6 months	+34.66%
Current year	+68.49%

Director	Title	Age	Since
Martine Rothblatt CEO	Chief Executive Officer	69	1996-06-25
Michael Benkowitz PSD	President	52	2016-06-25
James Edgemond DFI	Director of Finance/CFO	56	2015-03-12

Manager	Title	Age	Since
Raymond Kurzweil BRD	Director/Board Member	76	2001-12-31
Martine Rothblatt CHM	Chairman	69	1996-06-25
Louis Sullivan BRD	Director/Board Member	90	2001-12-31

Name	Weight	AuM	1st Jan change	Investor Rating
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD	3.06%	1 M€	-.--%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	2.87%	2 M€	-.--%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
UNITED THERAPEUTICS CORPORATION	-2.02%	-0.64%	+54.37%	+95.51%	16.54B
LONZA GROUP AG	+1.15%	+0.96%	+55.56%	-29.15%	43.12B
IQVIA HOLDINGS INC.	-0.29%	-0.49%	-6.19%	-22.49%	36.45B
CELLTRION, INC.	+0.32%	+7.78%	+14.79%	-4.17%	27.58B
ICON PUBLIC LIMITED COMPANY	-1.22%	-1.87%	-21.24%	-22.26%	17.36B
MODERNA, INC.	-0.76%	+4.74%	-44.58%	-87.78%	16.57B
BIO-TECHNE CORPORATION	-0.03%	+5.72%	+19.81%	-36.14%	11.97B
MEDPACE HOLDINGS, INC.	+0.49%	+0.85%	+25.82%	+64.23%	10.56B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.27%	+1.68%	+1.00%	-45.59%	10.18B
TEMPUS AI, INC	-0.62%	+6.81%	-	-	9.85B
Average	-0.33%	+3.25%	+11.04%	-9.76%	20.02B
Weighted average by Cap.	-0.12%	+2.49%	+15.18%	-14.04%

	2024 *	2025 *
Net sales	2.88B 2.73B 2.54B 2.27B 4.04B 244B 4.43B 31.47B 11.72B 100B 10.83B 10.59B 434B	3.18B 3.01B 2.8B 2.5B 4.46B 269B 4.88B 34.73B 12.93B 110B 11.95B 11.68B 479B
Net income	1.19B 1.13B 1.05B 939M 1.67B 101B 1.83B 13.03B 4.85B 41.4B 4.48B 4.38B 180B	1.29B 1.22B 1.14B 1.01B 1.8B 109B 1.98B 14.07B 5.24B 44.7B 4.84B 4.73B 194B
Net Debt	-2.16B -2.05B -1.91B -1.7B -3.03B -183B -3.32B -23.63B -8.8B -75.1B -8.13B -7.95B -326B	-3.29B -3.12B -2.9B -2.59B -4.61B -278B -5.06B -35.95B -13.39B -114B -12.37B -12.1B -496B